Screener
Immunovant, Inc. IMVT Business Segments — Interest Income (Expense), Nonoperating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Contractual costs related to batoclimab program discontinuation | 38,952 | — | — |
| Personnel-related research and development (1) | 128,534 | 111,499 | 74,290 |
| Acquired in-process research and development | — | — | 12,500 |
| Personnel-related general and administrative (2) | 48,730 | 41,095 | 34,684 |
| Other general and administrative (3) | 27,512 | 36,140 | 22,597 |
| Interest income, net | (25,330) | (24,732) | (24,948) |
| Other segment items (4) | (1,966) | 420 | 1,575 |
| Net loss | $505,606 | $413,840 | $259,336 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s business segments — interest income (expense), nonoperating?
- Immunovant, Inc. (IMVT) reported business segments — interest income (expense), nonoperating of $8.06M in Q1 2026.
- How has Immunovant, Inc.'s business segments — interest income (expense), nonoperating changed year-over-year?
- Immunovant, Inc.'s business segments — interest income (expense), nonoperating increased by 17.0% year-over-year, from $6.89M to $8.06M.
- What is the long-term trend for Immunovant, Inc.'s business segments — interest income (expense), nonoperating?
- Over 3 years (2023 to 2026), Immunovant, Inc.'s business segments — interest income (expense), nonoperating has grown at a 49.5% compound annual growth rate (CAGR), from $7.58M to $25.33M.
- What does business segments — interest income (expense), nonoperating mean?
- Represents the net impact of interest income earned on cash balances and interest expenses incurred on debt obligations for the segment. This metric highlights the non-operating financial performance and the company's ability to generate returns on its capital reserves. It provides insight into the segment's liquidity position and financial management efficiency.
Ask your AI about Immunovant, Inc.'s business segments — interest income (expense), nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude